Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
Bristol-Myers Squibb Co BMY
$62.86
▲ +2.21%
(+$1.36)
Index member:
S&P 500
⬆️ Above Yest. High
💰 High Dividend
Open
$61.75
Prev Close
$61.50
Day Range
$61.40 – $62.91
52W Range
$42.52 – $68.64
Market Cap
$125.63B
P/E (TTM)
13.65
Beta
0.20
Div Yield
4.58%
EPS (TTM)
$4.54
📋 Company Profile
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 1980-03-17 |
| Shares Out. | 2,042,070,000 |
| Website | bms.com ↗ |
| Phone | 13026587581 |
| Employees | 32,500 |
| Revenue | $12.97B |
| Gross Profit | $9.25B |
| Net Income | $3.32B |
| Free Cash Flow | $11.44B |
| Total Assets | $87.63B |
| Total Liabilities | $65.32B |
| Equity | $22.32B |
About Bristol-Myers Squibb Co
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Bristol-Myers Squibb Co is a publicly traded company under the ticker symbol BMY on the NEW YORK STOCK EXCHANGE, INC., operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
35 analysts (2026-09-01)
📰 Latest News for BMY
Dividend Champion, Contender, And Challenger Highlights: Week September 27
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026
Bristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug
Top Stock Reports for Tesla, Bank of America & Coca-Cola
Why Women-Run Companies Deserve a Place in Your Portfolio

